What are your top takeaways in Head & Neck Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Michigan
Answered on
In nasopharyngeal cancer, the group from Sun Yat-Sen University presented the results of a non-inferiority, randomized phase III study comparing RT alone vs RT concurrent with cisplatin for intermediate-risk patients (stage II and T3N0M0) (Ma et al., 2022 ASCO Annual Meeting, abstract #6000). They f...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · Banner M.D. Anderson Cancer Center
Answered on
Tata Memorial Docetaxel Trial (6003)
Takeaway: Docetaxel improved DFS and OS compared to RT alone in cisplatin-ineligible patients.
Details:
- 356 cisplatin-ineligible patients with locally advanced disease needing definitive or adjuvant CRT.
- Randomized to concurrent docetaxel 15 mg/m2 weekly for a ...
Join for free or sign in to see the full answer